Dermatology
| Alopecia Areata
Dermatology
Alopecia Areata
Patient Reported Outcomes for Scalp, Eyebrow and Eyelash hair loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 104 week Results from Two Phase 3 Clinical Trials
book_2
Source:
EADV Congress 2023 - Oral session
calendar_today
Published on Medfyle:
October 2023
import_contacts
4
min
In this medfyle
Alopecia areata impacts quality of life, and therefore patient-reported outcomes are important to assess treatment benefits. Pooled data from BRAVE-AA1 and -AA2 show that quality of life improvements correlate with regrowth of eyebrows and eyelashes, as well as on the scalp.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the EADV Congress 2023. The content is developed by Infomedica in collaboration with the EADV.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, or the EADV.
©2023 Infomedica. All rights reserved.
